Neurology & Neurosurgery Clinical Trials

Providing state-of-the-art care for people with brain and nervous system disorders is our most important commitment. As a neurology or neurosurgery patient at Cedars-Sinai, you have access to clinical trials and research aimed at improving testing methods, treatments, quality of life and recovery. These studies are open to people with a broad range of neurological conditions.

Questions? See the Clinical Trial FAQs.



Amyotrophic Lateral Sclerosis (ALS)

Condition:

Amyotrophic lateral sclerosis

Participants Must:

Be ages 18–100 years old; with familial or sporadic ALS diagnosed as possible, laboratory-supported probable, probable or definite.

Summary:

This study will collect specimens and data from patients with amyotrophic lateral sclerosis (ALS). The specimens will be used to create cells called induced pluripotent stem cells (iPSCs) and to collect DNA for ALS gene identification.

Condition:

Amyotrophic lateral sclerosis

Participants Must:

Be at least 18 years old; with diagnosis of clinically possible, laboratory supported probable, probable or clinically definite ALS.

Summary:

The objective of this study is to assess an investigational strength measurement device called Accurate Test of Limb Isometric Strength (ATLIS) in patients with amyotrophic lateral sclerosis (ALS). ATLIS is designed to evaluate muscle strength and measures the isometric strength of 12 muscle groups in the arms and legs.

Condition:

Amyotrophic lateral sclerosis

Participants Must:

Be confirmed with diagnosis of ALS; duration of symptoms ≤36 months.

Summary:

This study focuses on patients who have been diagnosed with amyotrophic lateral sclerosis (ALS), with symptoms present for less than three years. The study is designed to test the investigational use of CNS10-NPC-GDNF cells.

Condition:

Amyotrophic lateral sclerosis

Participants Must:

Be at least 18 years old; with diagnosis of familial or sporadic ALS, or those with primary lateral sclerosis or progressive bulbar/muscular atrophy forms of motor neuron disease.

Summary:

This study focuses on individuals who have been diagnosed with amyotrophic lateral sclerosis (ALS) or a related motor neuron disease (MND) such as primary lateral sclerosis, progressive muscular atrophy, or progressive bulbar palsy. The purpose of the study is to collect specimens and data for future analyses.

Condition:

Amyotrophic lateral sclerosis

Participants Must:

Be at least 18 years old; suspected, possible, probable, probable (lab-supported) or definite ALS.

Summary:

This study focuses on patients with amyotrophic lateral sclerosis (ALS) who have some changes in breathing. The purpose of the study is to examine the use of one airway clearance medical device compared to the use of two airway clearance medical devices together.

Condition:

Amyotrophic lateral sclerosis

Participants Must:

Be 18–80 years old; with diagnosis of familial or sporadic ALS.

Summary:

The purpose of this study is to examine an investigational drug called CK-2127107 as a potential therapy for the improvement of skeletal muscle function in patients with amyotrophic lateral sclerosis (ALS).

Condition:

Amyotrophic lateral sclerosis

Participants Must:

Be between 18–60 years old; with ALS diagnosed as possible, laboratory-supported probable, probable or definite.

Summary:

This study focuses on patients who have been diagnosed with amyotrophic lateral sclerosis (ALS) with symptoms less than two years. The study is designed to test the investigational use of NurOwn (MSC-NTF cells), a type of cell derived from an individual’s own bone marrow. Researchers aim to determine whether repeated dosing of NurOwn is safe without causing too many side effects and whether it may decrease the rate of ALS decline.

Brain Aneurysms

Condition:

Brain Aneurysms

Summary:

The purpose of this medical procedure is to treat an aneurysm with the liquid material Onyx® HD-500. The liquid material, which is placed within a brain blood vessel aneurysm, is expected to embolize (block or reduce blood flow) at the site of the aneurysm, which may help reduce symptoms in patients. Onyx® HD-500 is a Humanitarian Use Device (HUD), a designation for devices that will be used to treat fewer than 4,000 people a year.

Condition:

Aneurysms

Participants Must:

Be at least 18 years old; wide-neck, intracranial (within the skull), saccular (resembling a small sack) aneurysm which will be treated with bare metal coils.

Summary:

The purpose of this study is to evaluate the investigational use of the Neuroform Atlas Stent in patients with brain aneurysms. An aneurysm is a bulging (ballooning) of a blood vessel caused by a weakness in the vessel's wall.

Brain Tumors

Condition:

Brain tumors

Participants Must:

Be an adult and child identified as having a probable brain tumor which is best treated by surgical resection.

Summary:

The purpose of this study is to collect brain tumor samples taken during a scheduled surgical procedure to determine possible eligibility and interest in participating in current IRB-approved vaccine trials. The tumor tissue will be removed during the surgery regardless of research participation. The processed tumor tissue would then be maintained in a separate registry and analyzed for eligibility in any of the IRB-approved vaccine trials.

Condition:

Brain tumors

Participants Must:

Be an adult and pediatric patient; with a suspected or pathology-proven brain, breast, head, neck, or skin tumor who are undergoing a tumor resection; or undergoing temporal lobectomy as standard of care for epilepsy.

Summary:

The purpose of this study is to evaluate the investigational use of laser-induced fluorescence spectroscopy (LIFS) to detect brain tumors at the time of surgery. LIFS is a technique that utilizes a beam of light (laser) to differentiate tumor tissue from normal brain tissue.

Carotid Stenosis

Condition:

Carotid stenosis

Participants Must:

Be at least 35 years old; have no medical history of stroke or transient ischemic attack on the same side of the body as the stenosis (narrowing) within 180 days of study group assignment.

Summary:

This study evaluates differences between treatment options for patients with asymptomatic carotid stenosis (narrowing of the carotid arteries without symptoms). Carotid artery disease is caused by a thickened area (plaque) in the artery, which narrows the artery and may limit blood flow to the brain.

Charcot-Marie-Tooth (CMT) and Other Neuromuscular Disorders

Condition:

Charcot-Marie-Tooth disease

Participants Must:

Have documented, disease causing mutation in the MPZ gene (for CMT1B) or in MFN2 (for CMT2A); have two documented, disease causing mutations in the GDAP1 gene (for CMT4A) or two mutations in the SH3TC2 gene (for CMT4C).

Summary:

The purpose of this study is to determine the natural history, or speed of progression, of Charcot Marie Tooth disease (CMT). The study will follow a group of people over time who have, or are at risk of developing, CMT and will also include a group of participants (“controls”) who do not have CMT.

Summary:

The purpose of this study is to establish a repository of DNA and tissue samples to be used for future research studies investigating the clinical and genetic features of various types of neurologic and neuromuscular conditions.

Epilepsy

Condition:

Epilepsy

Participants Must:

Be at least 13 years old; with epilepsy undergoing surgical implantation of intracranial electrodes for continuous video-electroencephalography (EEG).

Summary:

This study focuses on individuals who have medically intractable epilepsy and are planning to, or have already undergone, insertion of electrodes into the brain to help find the source of seizures. The purpose of the study is to measure the activity of individual nerve cells (neurons) and collections of nerve cells (local field potentials) in the brain during simple learning, memory, decision-making or problem-solving tasks, as well as before and during voluntary movement.

Movement Disorders

Condition:

Movement disorders

Participants Must:

Be at least 18 years old; with movement disorder undergoing surgical implantation of DBS electrodes for treatment of a movement disorder.

Summary:

This study focuses on individuals who have a movement disorder and are undergoing surgical insertion of electrodes into the brain to treat their movement disorder. The purpose of the study is to measure the activity of individual nerve cells (neurons) and collections of nerve cells (local field potentials) in the brain during simple learning, memory, decision-making or problem-solving tasks, as well as before and during voluntary movement.

Multiple Sclerosis

Condition:

Multiple sclerosis

Participants Must:

Be at least 18 years old; with Neurologist-confirmed diagnosis of MS.

Summary:

The purpose of this study is to determine the effectiveness of an online program called Deprexis for the treatment of depressive symptoms in individuals with multiple sclerosis (MS). Deprexis was developed to treat depression; in this study, the program has been modified to address MS-specific depression symptoms.

Parkinson's Disease

Condition:

Parkinson's disease

Participants Must:

Be Hoehn and Yahr scale stage ≤3.0; ambulatory with or without assistance; agree to use medically accepted methods of contraception.

Summary:

The purpose of this study is to evaluate an investigational drug called EPI-589 in patients with mitochondrial subtype and sporadic idiopathic Parkinson’s disease. Mitochondrial subtype (also known as genetically defined subtypes) is a type of Parkinson’s disease with known genetic causes. Idiopathic is a type of Parkinson’s disease with unknown causes.

Condition:

Parkinson's disease, insulin resistance

Participants Must:

Be with diagnosis of idiopathic Parkinson's disease; concurrent enrollment in the study, Liraglutide in Parkinson's Disease.

Summary:

This study aims to determine the effects of a drug called liraglutide on brain glucose metabolism in Parkinson's disease (PD) patients. The study focuses on patients diagnosed with idiopathic PD who have already agreed to participate in another study, Liraglutide in Parkinson's Disease.

Condition:

Parkinson's disease

Participants Must:

Be between 25–85 years old; with diagnosis of idiopathic Parkinson's disease.

Summary:

The purpose of this study is to examine the safety and efficacy of an insulin resistance treatment drug, liraglutide, in patients with Parkinson’s disease (PD). Patients with PD commonly show glucose intolerance and may benefit from medications originally designed to treat insulin resistance.

Condition:

Parkinson's disease

Participants Must:

Be between 30–80 years old at time of enrollment.

Summary:

This study focuses on patients who have symptoms that are the precursors of Parkinson’s disease (PD), PD, or types of atypical PD. The purpose of the study is to determine whether using two imaging techniques together (myocardial scintigraphy and dopamine transporter scan) is a reliable method for detecting PD early, perhaps even before someone has obvious signs of the disease.

Condition:

Parkinson's disease

Participants Must:

Be at least 18 years old; with clinical diagnosis of Parkinson's disease.

Summary:

The purpose of this study is to examine the history of Parkinson's disease in patients. Researchers aim to learn about medical information, key dates, and treatment related to patients' disease. The study will also evaluate whether biomarkers can be useful in predicting the progression of Parkinson's disease.

Progressive Supranuclear Palsy

Condition:

Progressive supranuclear palsy

Participants Must:

Be at least 40 years old; meet criteria for possible or probable progressive supranuclear palsy.

Summary:

This study focuses on patients with progressive supranuclear palsy (PSP) who are over 40 years old. The purpose of the study is to evaluate an investigational drug called ABBV-8E12 and learn whether it could help slow down a disease called progressive supranuclear palsy (PSP). The study will also assess various doses of the drug and confirm its safety in patients with PSP.

Stroke

Condition:

Stroke

Participants Must:

Be between 18–80 years, inclusive; acute ischemic stroke, secondary to presumed blockage of blood vessel.

Summary:

The purpose of this study is to determine whether the investigational drug 3K3A-APC is safe at various dose levels in patients who have had a stroke and who have also received the "clot buster" drug tPA. 3K3A-APC may protect the brain after a stroke by keeping brain cells alive and by reducing inflammation.

Condition:

Stroke

Summary:

Data registries can be used to help researchers better identify patterns related to a particular disease or condition. This data registry research activity will enable investigators to review and study the medical records of many patients in order to better understand the causes, risks and treatment of stroke in children. The registry will also be used to develop and conduct potential research studies.

Condition:

Stroke

Participants Must:

Be between 18–80 years; National Institutes of Health Stroke Scale greater than or equal to eight.

Summary:

The purpose of this study is to assess the safety and effectiveness of the mechanical thrombectomy (physically removing a blockage in a blood vessel) compared to best medical therapy (treatment with the best use of available medicines) in stroke subjects who are able to begin treatment within 12 hours of symptom onset.

Condition:

Stroke

Participants Must:

Be between 30–80 years old. Patients 30 to 49 years old are required to meet additional criteria; with transient ischemic attack or non-severe stroke within 30 days of enrollment.

Summary:

This study focuses on patients who have been evaluated and/or treated by a neurosurgeon and/or neurologist at Cedars-Sinai for symptomatic intracranial stenosis. The purpose of the study is to evaluate the outcomes of a surgical approach called indirect revascularization (encephaloduroarteriosynangiosis or EDAS) for narrowing of the blood vessels in the brain.

Condition:

Stroke

Participants Must:

Be between 22–80 years old; have a Wingspan stent procedure attempted; provide informed consent.

Summary:

The purpose of this study is to fulfill a U.S. Food and Drug Administration requirement to collect information on the use of the Wingspan® Stent System with the Gateway® Percutaneous Transluminal Angioplasty Balloon Catheter, which has been approved as a Humanitarian Use Device.